NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview

BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph […]

Dpharm 2017 Summary now available

The Conference Forum was delighted to present the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference, with a full day dedicated to Mobile in Clinical Trials on Wednesday September 6. Mark your calendars, DPharm 2018 will take place, September 25-26 in Boston. We are dedicated to presenting the annual event that the life science industry can rely on for the latest thinking […]